The Paris Saclay Cancer Cluster association announces its official creation and the appointment of leaders

A global ambition for French oncology

Villejuif (France), February 4, 2022 – The Paris Saclay Cancer Cluster (PSCC) takes a new step with the creation of its legal structure and the appointment of leaders.

Announced by French President Emmanuel Macron as part of the CSIS in June 2021, the Paris Saclay Cancer Cluster is now organized as an association with its mission and ambitions presented today at Gustave Roussy, in the presence of Olivier Véran, Minister for Solidarity and Health, Frédérique Vidal, Minister for Higher Education, Research and Innovation and representatives of the five founding members: Sanofi, Gustave Roussy, Inserm, the Institut Polytechnique de Paris and Université Paris-Saclay.

The association is chaired by Eric Vivier, Professor at the Assistance Publique Hôpitaux de Marseille, Aix-Marseille University, a specialist in cancer immunology and an entrepreneur: he is one of the founders of Innate Pharma, a clinical stage biotechnology company, specializing in immuno-oncology. In addition, Benjamin Garel, who has headed the Martinique University Hospital for the past three years, will become the association's Managing Director.

By relying on a high-potential ecosystem centered on leading sources of oncology innovation: patients, hospitals, universities, start-ups, industry, investors, national research organizations and public authorities, the PSCC seeks to accelerate the availability of innovative treatments and the improvement of care, hope and quality of life for many people with cancer. The second leading cause of death in the world, cancer kills nearly 10 million people a year. Almost one in six deaths is due to cancer worldwide.

This ecosystem will develop on the outskirts of Paris, in Villejuif, on an area of several hectares in the heart of Greater Paris, very close to Gustave Roussy. The entities involved in the fight against cancer will be able to meet there and thus energize an entire region, with influence on France and Europe, strengthening the place of French excellence among the world’s best. In addition, a dedicated building, which will be at the heart of the PSCC, the “Oncology Prospective Center,” is planned to promote cooperation.

The association's offices will move to the Paul Brousse site this summer, pending the completion of construction.
A cluster and four pillars to transform science into value

To respond to the challenges of precision medicine and invent the oncology of tomorrow in France, Paris Saclay Cancer Cluster seeks to accelerate the maturation of innovative projects led by start-ups, biotech companies, industry and researchers, med-techs, e-techs and companies specializing in data, through an offer based on four pillars:

- **A collaborative, synergistic, and integrated interdisciplinary mode** allowing members to evolve within a unique place researchers, practitioners, academics, entrepreneurs, industry and investors come together. This mode will also make it easier to connect via a digital platform and to have an agile and balanced governance between stakeholders. The PSCC association plans to welcome 80 members in one year with a target of 200 members by 2027.

- **An ecosystem, concentrated in excellence**, with the possibility of exchanging with multidisciplinary, scientific and medical experts and access to training at a level of excellence as well as a multi-skilled mentoring offer.

- **Accelerating services and technologies** through a specialized technical platform bringing together a unique combination of research equipment, specialized support services to accelerate proof of concepts and easy access to samples.

- **Consolidated and enriched specialized data such** as deep and longitudinal data from several sources, storage and analysis infrastructure, expert support and acceleration via artificial intelligence.

The Paris Saclay Cancer Cluster will be fully part of the "France 2030" plan, announced by French President Emmanuel Macron in the field of health innovation.

Unique in Europe for its size and ambition, the Paris Saclay Cancer Cluster project is based on the strong commitment of its founding members. Its international scope will position France among the world leaders in transforming science into value in the field of oncology.

“I am delighted to be involved in the Paris Saclay Cancer Cluster alongside many entities in cancer research,” said Pr. Eric Vivier, PhD, DVM, Scientific Director of Innate Pharma, University Professor - Hospital Practitioner and President of the Paris Saclay Cancer Cluster association. “The PSCC aims to bring together in the same region in the south of Paris expertise ranging from biology to medicine, including bioinformatics and the use of artificial intelligence, so as to discover the medicines of tomorrow that will transform the lives of cancer patients.”

"We are going to establish a dynamic and motivated team to help companies access the market as quickly as possible,” said Benjamin Garel, Managing Director of the Paris Saclay Cancer Cluster association. “A part will be dedicated to the shared laboratory offer, another part to the data project and a last part to promote the establishment of companies, training and research laboratories on the cluster. We will also work in a
network with other hospitals and structures that wish to participate in this momentum for innovation in the service of patients. I am delighted to join this wonderful adventure."

For more information on the Paris Saclay Cancer Cluster: [https://pscc.paris/](https://pscc.paris/)

**Eric Vivier**
University Professor - Hospital Practitioner, Doctor in Immunology from Paris-Saclay University and trained at Harvard, Eric Vivier directed the Marseille-Luminy Immunology Center, a research center under the supervision of Inserm, CNRS and from Aix Marseille University, from 2008 to 2017. Combining research and entrepreneurship, he is one of the founders of the biopharmaceutical company Innate Pharma, of which he is now scientific director. He is also one of the founders of Marseille Immunopôle, an immunology cluster.

**Benjamin Garel**
A polytechnician engineer, Benjamin Garel worked for several years within the framework of competitiveness clusters, in the regions and at the General Directorate for State Modernization. He then worked as Director of Quality at the Grenoble University Hospital, Director of Operations at the AP-HP and he managed the Martinique University Hospital for 3 years.

**About Gustave Roussy**
Ranked first in Europe and among the top institutes in the world in the fight against cancer, Gustave Roussy constitutes a center of global expertise entirely dedicated to cancer patients. A source of therapeutic innovations and diagnostic advances, the Institute welcomes nearly 50,000 patients each year and develops an integrated approach between research, care and teaching. An expert in rare cancers and complex tumours, Gustave Roussy treats all cancers, at all stages and all ages of life. It offers its patients personalized care that combines innovation and humanity, where care is taken into account as well as the physical, psychological and social quality of life. With 4,100 professionals spread over two sites, Villejuif and Chevilly-Larue, Gustave Roussy brings together the expertise essential for high-level cancer research; a quarter of the patients treated are included in clinical trials. For more information: [www.gustaveroussy.fr](http://www.gustaveroussy.fr)

**About Sanofi**
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

**About Inserm**
Inserm: science for health. Created in 1964, the National Institute of Health and Medical Research (Inserm) is a public scientific and technological institution, placed under the dual supervision of the Ministry of Higher Education, Research and Innovation and the Ministry of Solidarity and Health. Inserm is the only French public organization dedicated to biological, medical and human health research and is positioned on the entire path from the research laboratory to the patient's bedside. Its researchers are dedicated to the study of all diseases, from the most frequent to the rarest. To this end, most of its laboratories are located as close as possible to places of care and education. This structure is a guarantee of success, through the pooling of skills, attractiveness for talent and proximity to patients. With a budget of nearly one billion, Inserm supports more than 280 laboratories spread across France. All the teams bring together nearly 14,000 researchers, engineers, technicians, managers, hospital-university students, post-doctoral students... Since 2020, Inserm has been one of the leading French players in the fight against Covid-19. 19. [www.inserm.fr](http://www.inserm.fr)
About the Institut Polytechnique de Paris
The Institut Polytechnique de Paris (IP Paris) is a public institution of higher education and research that brings together five major French engineering schools: École polytechnique, ENSTA Paris, ENSAE Paris, Télécom Paris and Télécom South Paris. Under the aegis of the Institute, they pool their expertise in order to pursue two major ambitions: to develop training programs of excellence and cutting-edge research. Thanks to the academic roots of its five founding schools and its alliance with HEC, IP Paris is positioned as a leading teaching and research institution in France and internationally. www.ip-paris.fr

About Université Paris-Saclay
Université Paris-Saclay brings together ten constituent faculties and institutes, four Grandes Écoles, the Institut des Hautes Études Scientifiques, two associate institutions and shared laboratories with six national research organisations. With 48,000 students, 8,100 lecturers and 8,500 administrative and technical staff members, Université Paris-Saclay offers a comprehensive and varied range of undergraduate to doctorate level programmes and engineering degrees, renowned for their quality thanks to the reputation and commitment of the University’s academic staff. Located in the south of Paris on vast sites that stretch across Paris, Orsay, Évry and Versailles, Université Paris-Saclay benefits from a strategic geographical and socio-economic position that is strengthened by its international visibility. A leading university, Université Paris-Saclay is recognised for its excellent Mathematics and Physics programmes but also for Biological and Medical Sciences, Agriculture, Engineering, and its extensive Humanities and Social Sciences courses. Close to Paris, Université Paris-Saclay is nested in a protected natural area, at the heart of a dynamic economic hub.

Media Relations Contacts

Sanofi
Chrystel Baude
Tel: +33 6 70 98 70 59
Email: chrystel.baude@sanofi.com

Gustave Roussy
Claire Parisel
Tel: +33 6 17 66 00 26
Email: claire.parisel@gustaveroussy.fr

Inserm
Priscille Riviere
Tel: +33 6 89 32 87 74
Email: presse@inserm.fr

Polytechnic Institute of Paris
Mathilde Ordas
Tel: +33 6 30 30 02 62
Email: mathilde.ordas@polytechnique.edu

Université Paris-Saclay
Gaelle Degrez
Tel: +33 6 21 25 77 45
Email: gaelle.degrez@universite-paris-saclay.fr